

ONX-0914

Catalog No: tcsc1625



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

960374-59-8

Formula:

$C_{31}H_{40}N_4O_7$

Pathway:

Metabolic Enzyme/Protease

Target:

Proteasome

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 35 mg/mL (60.28 mM)

Alternative Names:

PR-957

Observed Molecular Weight:

580.67


Product Description

ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

IC50 Value: ~10 nM [1]

in vitro: PR-957 blocked presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo. Selective inhibition of LMP7 by PR-957 blocked production of interleukin-23 (IL-23) by activated monocytes and interferon-gamma and IL-2 by T cells [1].

in vivo: In mouse models of rheumatoid arthritis and lupus, ONX-0914 treatment reverses signs of disease and results in reductions in cellular infiltration, cytokine production and autoantibody levels at well-tolerated doses. The maximum tolerated dose (MTD) of ONX-0914 in mice to be 30 mg/kg body weight. IFN-g release is inhibited by ~60% at LMP7-selective concentrations of ONX-0914 and by ~90% at higher concentrations. Production of IL-2 is also inhibited by ~50% [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!